Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1864 results
June 2022
-
Press Release
New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer
Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS… -
Press Release
Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa
Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed… -
Statement
Novartis resumes business in Ukraine
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
May 2022
-
Press Release
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap… -
Press Release
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from… -
Story Discovery
How Emily’s act of bravery inspired a wave of continued innovation
Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.
-
Press Release
Sandoz appoints new Board representative to global AMR Industry Alliance
Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life… -
Story Access to Healthcare
Boosting access to cancer care where it’s needed most
Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.
-
Press Release
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these… -
Press Release
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new… -
Press Release
Novartis provides update on production of radioligand therapy medicines
Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of… -
Press Release
Novartis receives European Commission approval for Jakavi® to be the first post-steroid treatment for acute and chronic graft-versus-host disease
Jakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…